Compare LUV & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUV | GMAB |
|---|---|---|
| Founded | 1967 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3B | 19.1B |
| IPO Year | 1995 | N/A |
| Metric | LUV | GMAB |
|---|---|---|
| Price | $40.39 | $25.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 7 |
| Target Price | ★ $44.92 | $40.93 |
| AVG Volume (30 Days) | ★ 8.9M | 1.4M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.82 | $17.80 |
| Revenue Next Year | $4.63 | $14.86 |
| P/E Ratio | $49.84 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.82 | $17.24 |
| 52 Week High | $55.11 | $35.43 |
| Indicator | LUV | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 34.14 |
| Support Level | $30.46 | $21.13 |
| Resistance Level | $44.28 | $33.75 |
| Average True Range (ATR) | 1.90 | 0.60 |
| MACD | -0.35 | -0.06 |
| Stochastic Oscillator | 22.57 | 25.45 |
Southwest Airlines is the largest domestic air carrier in the United States by passengers boarded. Southwest operates nearly 800 aircraft in an all-Boeing 737 fleet. Despite offering some longer routes and a few perks for business travelers, the airline predominantly specializes in short-haul, leisure flights operated in a single, open-seating cabin configuration in a point-to-point network. In early 2026, Southwest will modify its cabins to offer some rows with extra legroom and will update its ticketing process and merchandising to offer assigned seats and more fare categories, including a basic economy class that will more directly compete with other airlines' offerings and appear for the first time in travel aggregators' search results.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.